HR+/HER2- metastatic breast cancer, CDK4/6 inhibitor resistance, Systematic Review, Network meta-analysis, Biomarker-driven therapy, Antibody-drug conjugates
HR+/HER2- advanced breast cancer, CDK4/6 inhibitors, Real-world, progression-free survival, Lobular histology, PALMARES-2
Breast Cancer, HER2-low, machine-learning
breast cancer, HER2-low, machine-learning